Compare Fidelity National Information Servcs Inc (FIS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs GeneDx Holdings Corp — how do they compare? Fidelity National Information Servcs Inc trades at $34.2 (market cap $17.71B), while GeneDx Holdings Corp trades at $69.42 (market cap $2.02B). The key difference: Fidelity National Information Servcs Inc is far larger — about 8.8× GeneDx Holdings Corp's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and GeneDx Holdings Corp for 19 Days on average.
| FIS | WGS | |
|---|---|---|
Market Cap | $17.71B | $2.02B |
Volume | 9,047,825 | 734,640 |
Sector | Technology | Health |
52-Week High | $68.57 | $167.51 |
52-Week Low | $32.44 | $34.51 |
Typical Hold Time | 88 Days | 19 Days |
Enterprise Value | $38.22B | $2.05B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal despite beating earnings estimates in two of the last three quarters. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while analyst consensus remains strongly bullish with a $47.15 price target. Recent business developments include multiple core banking platform wins and new embedded banking offerings, signaling growth momentum in financial technology services.
The outlook appears positive given FIS's improving profitability trajectory and strong analyst support, though investors should monitor debt levels and execution risks. With revenue projected to grow to $12.2B in 2026 and net income margin expanding to 27.64%, the stock offers fundamental upside potential if the company can maintain its competitive positioning in banking technology modernization.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
